Sensible Medical Innovations

What Sensible Medical Innovations does

Sensible Medical Innovations is an Israel-based privately held medical device company founded in 2007, headquartered in Netanya with a US sales office in Raleigh, North Carolina. The company develops and commercializes the ReDS (Remote Dielectric Sensing) Pro System, a non-invasive lung fluid monitoring device that uses low-power radio frequency electromagnetic waves to measure the dielectric properties of lung tissue. The system delivers quantitative pulmonary congestion readings within 45 seconds and is positioned for heart failure management across the continuum of care, from inpatient discharge decision-making through outpatient follow-up, medication optimization, and readmission reduction. Target customers include hospitals, health systems, outpatient cardiology and heart failure clinics, skilled nursing facilities, nursing homes, home healthcare agencies, and US VA Medical Facilities.

The ReDS Pro System consists of a wearable chest sensor and a bedside monitor console that emits and receives RF signals through the patient's lung tissue, exploiting the differing dielectric properties of fluid-filled versus air-filled lung tissue to produce absolute lung fluid percentage readings. The device is FDA-cleared for pulmonary congestion assessment and is restricted by US Federal law to sale by or on the order of a physician. The ReDS platform is HIPAA and GDPR compliant and is supported by a clinical evidence base that includes the ReDS-SAFE HF randomized controlled trial published in JACC Heart Failure in 2024, which reported a 91% reduction in heart failure readmissions with ReDS-guided management, plus real-world data from Mount Sinai showing a 79% reduction in 30-day cardiovascular readmissions.

Sensible Medical's revenue model is anchored on hardware sales of the ReDS Pro System to enterprise healthcare buyers, complemented by point-of-care testing services. The company employs a direct enterprise sales motion targeting physicians and healthcare systems, supplemented by channel partner distribution through Wellesta for Southeast Asia and India and a Federal Supply Schedule for VA Medical Facilities in the US. Named customers and clinical study partners include Mount Sinai Hospital, Cone Health, Ohio State University, and Zhongshan Hospital Fudan University. The company has 11-50 employees, secured one disclosed $20 million funding round in 2013 led by Boston Scientific with Genesis Partners and SCP Vitalife Partners, and was recognized by TIME as one of the World's Top HealthTech Companies in 2025.

Name

Sensible Medical Innovations

Legal name

Sensible Medical Innovations LTD.

Website

https://sensible-medical.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Sensible Medical Innovations is a private Israeli medical device company that develops the ReDS Pro System, a non-invasive radio frequency lung fluid monitor for heart failure management, selling to hospitals, outpatient clinics, VA medical facilities, and skilled nursing facilities globally.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Chronic Disease Remote Monitoring (COPD/CHF/HTN, Weight & Symptom Tracking) (HLAHACAI)

akta.pro secondary industries

Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate) (HLAHAGAI), Home Patient Monitoring & Telehealth Devices (Vitals, Fall Detection, PERS) (HSABAKAE), Respiratory & Sleep Therapy Equipment (Oxygen, CPAP/BiPAP, Nebulizers) (HSABAKAD)

Keywords

• Heart failure monitoring
• Pulmonary congestion assessment
• Non-invasive medical device
• Lung fluid measurement
• Remote dielectric sensing

Headquarters

HQ city

Netanya

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain, Infrastructure

Revenue model

1. Medical Device Sales: Sale of ReDS Pro System and related monitoring equipment to healthcare providers including hospitals, outpatient clinics, skilled nursing facilities, and home healthcare. Federal law restricts device sale to or on the order of a physician.
2. Point-of-Care Testing Services: Non-invasive pulmonary congestion assessment services provided at various points of care including hospitals, emergency departments, hospital floors, and outpatient clinics using the ReDS system.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

Sensible Medical Innovations develops and sells the ReDS (Remote Dielectric Sensing) Pro System, a non-invasive medical device that uses low-power radio frequency electromagnetic waves to measure lung fluid content in approximately 45 seconds. The system supports heart failure management by providing absolute, quantitative pulmonary congestion readings at the point of care across hospitals, outpatient clinics, skilled nursing facilities, and home healthcare settings.

Product overview

Sensible Medical Innovations offers the ReDS™ Pro System—a single, unified non-invasive medical device for heart failure management. The system uses Remote Dielectric Sensing technology to measure pulmonary congestion by emitting low-power electromagnetic waves through lung tissue. It consists of a wearable sensor placed on the patient's chest, a bedside monitor console, and delivers lung fluid percentage readings within 45 seconds. The product is designed for use across multiple care settings including hospitals, outpatient clinics, skilled nursing facilities, and home healthcare.

Differentiator

Problem solved

Functional benefit

Brands

• ReDS (Remote Dielectric Sensing): Non-invasive system for monitoring and management of pulmonary congestion in patients with heart failure and other chronic diseases requiring lung fluid level monitoring. Provides 45-second pulmonary congestion assessment using radio frequency technology.

Products and services

• ReDS Pro System Non-invasive Remote Dielectric Sensing medical device that emits low-power electromagnetic waves through lung tissue to measure dielectric properties and provide absolute lung fluid percentage readings within 45 seconds. Includes a wearable chest sensor and bedside monitor console for use in hospitals, outpatient clinics, skilled nursing facilities, and home healthcare. Federal (U.S.) law restricts sale to or on the order of a physician.

Quantifiable outcome

• 91% reduction in heart failure readmission with ReDS-guided HF management (ReDS-SAFE HF Trial, JACC HF 2024)
• +4 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• WellestacoreChannel Partner/ Reseller/ Distributor · 1 January 2025Strategic partnership for commercialization of ReDS Pro in Southeast Asia (SEA) and India. The collaboration leverages Wellesta's strong market presence, established reputation, and expertise in healthcare distribution to expand access to ReDS technology across new territories. This enables clinicians to easily assess pulmonary congestion across the continuum of care and optimize management of heart failure patients.

Scale indicators5 records

Recent moves4 records

Expansion highlights2 records

Broad incumbents

• Medtronic: Global medtech incumbent with cardiac diagnostics, heart failure devices (e.g., ICDs, cardiac monitoring), and LINQ insertable cardiac monitor franchises. Medtronic competes for hospital heart failure budgets and could bundle lung fluid monitoring into its cardiac diagnostic ecosystem, posing a long-term bundling threat to Sensible Medical.
• Edwards Lifesciences: Large medtech company with established hemodynamic monitoring portfolio (e.g., Swan-Ganz, FloTrac) used in heart failure and critical care. While not directly competing on RF lung fluid measurement, Edwards overlaps with Sensible Medical in the heart failure/critical care monitoring space and could expand into pulmonary fluid monitoring via its installed base.
• GE HealthCare: Major patient monitoring and imaging incumbent with broad hospital footprint. GE's monitoring and imaging businesses overlap with Sensible Medical's hospital sales motion; its installed base could be used to introduce competing or complementary lung fluid measurement tools.
• Philips (Patient Monitoring): Philips Patient Monitoring division sells ICU/ward monitoring platforms used in hospitals for vitals and hemodynamic assessment. While Philips doesn't currently offer an RF-based lung fluid sensor, it competes for the same hospital monitoring budget and could acquire or develop a competing technology.
• Cheetah Medical (now part of Baxter): Cheetah Medical (acquired by Baxter) developed the NICOM non-invasive cardiac output monitor, used in heart failure and critical care. Represents a comparable non-invasive hemodynamic monitoring technology now owned by a major medtech incumbent, illustrating the strategic interest in this category.

Emerging players

• Procyrion: Developer of the Aortix percutaneous mechanical circulatory support device for heart failure. While the therapeutic focus differs, Procyrion targets the same heart failure patient population and competes for hospital cardiology budget attention.
• Bodyport: Cardiac-focused startup developing a non-invasive cardiac scale that measures hemodynamic signals (including lung fluid) via the feet. Targets the same heart failure monitoring use case as ReDS but with a different sensor modality, making it a direct emerging competitor in non-invasive HF monitoring.
• Vectorious Medical Technologies: Israel-based medtech company developing an implantable left-atrial pressure sensor (V-LAP) for heart failure monitoring. Targets a similar HF management use case as Sensible Medical but with an invasive implant approach, representing an alternative clinical paradigm for the same end goal.
• Telos Health Solutions: Provider of remote patient monitoring services for chronic conditions including heart failure. While not a direct device competitor, Telos addresses the same HF outpatient monitoring segment with a services-led approach, potentially competing for HF readmission-reduction budgets that Sensible Medical targets.

Regional players

• INFOPIA (now merged/affiliated entities in non-invasive monitoring): South Korean medical device company with non-invasive monitoring products. As Sensible Medical expands into Asia via Wellesta, regional non-invasive monitoring companies like Infopia represent potential local competitors in SEA markets where Sensible is targeting commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

• Xx.com/sensiblemedical
• YouTubeyoutube.com/channel/UCeTy3Ifw980KCHd5_hcnKEQ
• LinkedInlinkedin.com/company/1079315
• Facebookfacebook.com/sensiblemedicalltd

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sensible Medical Innovations